Elicio Therapeutics Inc.

11/21/2024 | Press release | Distributed by Public on 11/21/2024 15:07

Proxy Results Form 8 K

Item 5.07. Submission of Matters to a Vote of Security Holders.
On November 21, 2024, Elicio Therapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the stockholders of the Company considered and voted on three proposals, each of which was described in detail in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on September 27, 2024 (the "Proxy Statement"). 7,452,994 shares of Common Stock voted, representing 69.17% of the voting power of all shares entitled to vote at the Annual Meeting, which represented a quorum for the Annual Meeting.
At the Annual Meeting, the stockholders voted on proposals to: (1) elect three directors to hold office for three-year terms, (2) ratify the appointment of Baker Tilly US, LLP, as the Company's independent registered public accounting firm for the fiscal year ending 2024, and (3) approve, for purposes of complying with Nasdaq Listing Rule 5635(b), the issuance of shares of common stock issuable upon the exercise of certain warrants and conversion of that certain convertible note, as further detailed in the Proxy Statement.
Set forth below are the final voting results for each proposal submitted to a vote of the stockholders at the Annual Meeting. More information on the proposals can be found in the Proxy Statement.
Proposal 1: To elect three nominees to serve as the Company's Class I Directors to hold office for a three-year term or until their respective successors are elected and qualified.
Nominee For Against Abstain Broker Non-Votes
Robert Connelly

 		6,248,397 103,851 15,167 1,085,579
Yekaterina (Katie) Chudnovsky 6,233,264 118,343 15,706 1,085,681
Allen R. Nissenson, M.D. 6,249,739 102,488 15,086 1,085,681
Proposal 2: To ratify the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending 2024.
For Against Abstain Broker Non-Votes
7,434,248 1,188 17,558 0
Proposal 3: To approve, for purposes of complying with Nasdaq Listing Rule 5635(b), the issuance of shares of common stock issuable upon the exercise of certain warrants and conversion of that certain convertible note.
For Against Abstain Broker Non-Votes
6,269,593 81,508 16,130 1,085,763
Each of the director nominees and proposals received the necessary votes in favor to be adopted by the Company's stockholders at the Annual Meeting.